ArticleScientific reports2024
Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Confronting mortality: A meta-analysis and systematic review of psychedelic experiences and death anxiety.Journal of psychopharmacology (Oxford, England) · 2026Pooled it
- Real-World Psilocybin Therapy for Treatment-Resistant Depression: A Retrospective Observational Study.The Lancet regional health. Europe · 2026Article
- Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders.Palliative medicine · 2026Article
- Psilocybin in Neuropsychiatric Disorders: Seeking Valuable Evidence in History, Pure Science, Clinical Trials and Real-World Data (RWD).Brain sciences · 2026Review
- Designing evaluation infrastructure for psychedelic harm reduction at events: a methodological framework with formative mixed-methods field application.Frontiers in public health · 2026Article
- Home-based psilocybin-assisted therapy for a patient with advanced cancer: A case report.Palliative & supportive care · 2025Article
- The Emergence of Psilocybin in Psychiatry and Neuroscience.Pharmaceuticals (Basel, Switzerland) · 2025Review
- A Rapid Review of Psychedelic-Assisted Therapy in the Context of Palliative Care.Journal of hospice and palliative nursing : JHPN : the official journal of the Hospice and Palliative Nurses Association · 2025Article
- ExploringJournal of fungi (Basel, Switzerland) · 2025Review
- Expanded access to psychedelic treatments: comparing American and Canadian policies.General psychiatry · 2025Article
- Healthcare Providers' Perspectives on Psychedelic-Assisted Therapies Across Clinical Contexts: "I Can Offer Medical Assistance in Dying, but I Can't Prescribe Psychedelics".Global advances in integrative medicine and healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent clinical trials have found that the serotonergic psychedelic psilocybin effectively alleviates anxiodepressive symptoms in patients with life-threatening illnesses when given in a supportive environment. These outcomes prompted Canada to establish legal pathways for therapeutic access to psilocybin, coupled with psychological support. Despite over one-hundred Canadians receiving compassionate access since 2020, there has been little examination of these 'real-world' patients. We conducted a prospective longitudinal survey which focused on Canadians who were granted Section 56 exemptions for legal psilocybin-assisted psychotherapy. Surveys assessing various symptom dimensions were conducted at baseline, two weeks following the session (endpoint), and optionally one day post-session. Participant characteristics were examined using descriptive statistics, and paired sample t-tests were used to quantify changes from baseline to the two-week post-treatment endpoint. Eight participants with Section 56 exemptions (four females, M
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.